Results 41 to 50 of about 19,804 (260)

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan

Drugs - Real World Outcomes
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018.
Akina Takami, Gen Terashima, Takumi Tajima, Koki Yamashita, Ataru Igarashi   +4 more
doaj   +1 more source

Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis

Journal of Nepal Health Research Council, 2021
Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya, Bhojraj Adhikari, Manisha Bhochhibhoya, Shweta Nakarmi   +3 more
doaj   +1 more source

Enhanced Antibacterial Properties of Lyotropic Liquid Crystalline Nanoparticles via Curvature Modulation

Advanced Science, EarlyView.
Lipid nanostructured particles with increasing negative Gaussian curvature progress from vesicles to P‐cubosomes and D‐cubosomes. This curvature hierarchy enhances interaction with bacterial membranes, promotes membrane remodeling and leakage, and potentiates daptomycin activity against MRSA.
Xiangfeng Lai, Shuhong Wang, Chenguang Ding, Xenia Kostoulias, Anton P. Le Brun, Hsien‐Yi Hsu, Jhih‐Hang Jiang, Yajun Wang, Richard A. Strugnell, Anton Y. Peleg, Hsin‐Hui Shen   +10 more
wiley   +1 more source

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Diabetes, Metabolic Syndrome and Obesity, 2020
Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +
Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M   +6 more
doaj  

Flanking‐Group Engineering Unlocks Emerging Functionalities in Diketopyrrolopyrrole Semiconductors

Advanced Science, EarlyView.
This review presents a comprehensive and unified perspective of flanking‐group engineering in Diketopyrrolopyrrole (DPP) based organic semiconductors that connects molecular‐level design with cross‐device functionalities. By integrating insights from molecular design, solid‐state packing, and device physics, this review seeks to establish general ...
Xiaoyun Wu, Shanshan Zhou, Meng Li, Aung Ko Ko Kyaw, Xiao‐Lei Shi, Qian Liu   +5 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4).
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda   +10 more
doaj   +1 more source

Oral Delivery Systems for Food‐Derived Bioactive Peptides: Enhancing Stability, Bioavailability, and Health Benefits

Advanced Science, EarlyView.
Advanced delivery systems—including nanoparticles, nanoemulsions, liposomes, and hydrogels—protect food‐derived bioactive peptides from gastrointestinal degradation and bitterness. These systems enable pH‐responsive release, enhance intestinal absorption, and improve therapeutic efficacy against oxidative stress, metabolic disorders, cancer, and ...
Yu Xu, Fan Li, Runan Zhao, Tao Shu, Weihong Min, Bei‐Wei Zhu   +5 more
wiley   +1 more source

Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data

BMC Medicine
Background Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen, James Cheng-Chung Wei, Fu-Shun Yen, Chen-Yu Sung, Yu-Han Huang, Teng-Shun Yu, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +8 more
doaj   +1 more source

Multifunctional Manganese Oxide Nanocomposite Hydrogel With Synergistic Reactive Oxygen Species‐Scavenging, Oxygen‐Generating, Immunomodulatory, and Photothermal Antimicrobial Activities for Enhanced Diabetic Wound Healing

Advanced Science, EarlyView.
CFP/PC@MnO2 hydrogel integrates ROS scavenging, oxygen delivery, oxidative stress reduction, immunomodulation, and photothermal antibacterial properties. The incorporation of PC@MnO2 NPs endows the hydrogel with multiple functional advantages tailored to the pathological microenvironment of diabetic wounds, including efficient ROS clearance, mitigation
Zhi Xu, Xiaodong Luo, Jingxian Wu, Chaoyang Huang, Zhuoying Yang, Yixiang HePeng, Bosong Zhou, Xiang Li, Ruiyuan Liu, Xu Wu   +9 more
wiley   +1 more source

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor [PDF]

Zhongguo quanke yixue
The prevalence rate of type 2 diabetes is increasing year by year. It is known that oxidative stress and inflammation can participate in the occurrence and development of diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can enhance the incretin effect
ZHU Jing, XIE Ji, HU Xiaoxia
doaj   +1 more source